Tracking how well patients complete early breast cancer treatment

This is a real-world study that follows patients with early-stage, HER2-negative breast cancer who are starting treatment with Olaparib. Researchers want to understand how many patients are able to complete the full course of this medication as prescribed by their doctors. By tracking actual patient experiences in French hospitals, the study aims to identify any barriers to completing treatment and find ways to help patients succeed.

When a new medication becomes available for cancer treatment, doctors need to know how well it works in everyday practice—not just in controlled research settings. This study helps answer that question by observing whether patients can tolerate and complete this medication as intended, which will inform how to best support future patients.